Trial Profile
A Phase 2, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients with Diabetic Kidney Disease (DKD) who are Receiving Irbesartan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Irbesartan/propagermanium (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms ACTION
- Sponsors Dimerix Bioscience
- 21 Apr 2021 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 13 Sep 2018 Planned End Date changed from 30 Sep 2019 to 27 Dec 2019.